Diabetes

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Summary

Background

Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.

Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19

Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D'Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro

Diabetes Care 2021 July 12

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

June 25, 2021

DOI: 10.1056/NEJMoa2107519

Abstract

BACKGROUND

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Diabetes Care 2021 January 4

PMID: 33397768

DOI: 10.2337/dc20-1473

 

 

Abstract

Objective: To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin.

Actualización del diagnóstico de hiperglucemia gestacional durante la pandemia COVID-19

Endocrinología, Diabetes y Nutrición

Vol. 67. Núm. 8.

páginas 545-552 (Octubre 2020)

DOI: 10.1016/j.endinu.2020.05.002

Mercè Codina, Rosa Corcoy, María M. Goya, en representación del GEDE Consenso del Grupo Español de Diabetes y Embarazo (GEDE) 

DOCUMENTO DE CONSENSO